| [Objectives] To investigate the effect of Kidney-benefiting and Spleen-fortifying Pill on microinflammatory state in patients with uremia undergoing maintenance hemodialysis.[Methods] Twenty patients with chronic renal failure during maintenance hemodialysis were randomly selected as the therapy group administrated with Kidney-benefiting and Spleen-fortifying Pill and twenty normal individuals were selected as the normal control group. The serum levels of C-reactive protein(CRP), interlukin-6 (IL-6) and the plasma level of endotoxin of each patient before and after treatment were measured respectively and compared with that of other patients and that of the normal control group.[Results] 1. Compared with the normal control group, the serum level of CRP and the plasma level of endotoxin were significantly higher in the therapy group (p<0.01). The serum level of CRP and the plasma level of endotoxin was markedly lowered after treatment (p<0.05).2. Compared with the normal control group or the therapy group after treatment, the serum level of IL-6 showed no significant difference in the therapy group before treatment (p>0.05).3. Cumulative scores of clinical symptoms after treatment decreased than that before treatment(p<0.05).4. The serum levels of K+ in therapy group before and after treatment were both in the normal range and there was no significant difference between the two groups (p>0.05).[Conclusions] Kidney-benefiting and Spleen-fortifying Pill can reduce the serum level of CRP and the plasma level of endotoxin, which proves that Kidney-benefiting and Spleen-fortifying Pill can improve the microinflammatory state in patients with uremia undergoing maintenance hemodialysis in the certain extent. In addition, Kidney-benefiting and Spleen-fortifying Pill is beneficial in reducing the clinical symptom score without increasing the serum level of K+.
|
PDF Full Text Request